Treatment Time Optimization in Single Fraction Stereotactic Ablative Radiation Therapy: A 10-Year Institutional Experience

Gaudreault, M; Yeo, A; Kron, T; Hanna, GG; Siva, S; Hardcastle, N

Author(s): Gaudreault, M; Yeo, A; Kron, T; Hanna, GG; Siva, S; Hardcastle, N;
Details: Publication Year 2022-09,Volume 7,Issue #5,Page 100829
Journal Title: Advances in Radiation Oncology
Publication Type: Research article
Abstract: PURPOSE: Stereotactic ablative radiation therapy (SABR) delivered in a single fraction (SF) can be considered to have higher uncertainty given that the error probability is concentrated in a single session. This study aims to report the variation in technology and technique used and its effect on intrafraction motion based on a 10 years of experience in SF SABR. METHODS AND MATERIALS: Records of patients receiving SF SABR delivered at our instruction between 2010 and 2019 were included. Treatment parameters were extracted from the patient management database by using an in-house script. Treatment time was defined as the time difference between the first image acquisition to the last beam off of a single session. The intrafraction variation was measured from the 3-dimensional couch displacement measured after the first cone beam computed tomography (CBCT) acquired during a treatment. RESULTS: The number of SF SABR increased continuously from 2010 to 2019 and were mainly lung treatments. Treatment time was minimized by using volumetric modulated arc therapy, flattening filter-free dose rate, and coplanar field (24 +/- 9 min). Treatment time increased as the number of CBCTs per session increased. The most common scenario involved both 2 and 3 CBCTs per session. On the average, a CBCT acquisition added 6 minutes to the treatment time. All treatments considered, the average intrafraction variation was 1.7 +/- 1.6 mm. CONCLUSIONS: SF SABR usage increased with time in our institution. The intrafraction motion was acceptable and therefore a single fraction is an efficacious treatment option when considering SABR.
Department(s): Physical Sciences; Radiation Oncology
PubMed ID: 36148377
Publisher's Version: https://doi.org/10.1016/j.adro.2021.100829
Open Access at Publisher's Site: https://doi.org/10.1016/j.adro.2021.100829
Terms of Use/Rights Notice: Refer to copyright notice on published article.

Creation Date: 2024-10-25 06:46:50

Last Modified: 2024-10-25 06:48:14